Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 3
Submit an article Journal homepage
589
Views
79
CrossRef citations to date
0
Altmetric
Theme: Demyelinating Diseases - Review

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

Lisa Costelloe University Neurology Unit, Box 165, Level 5 Block A, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK. [email protected]
,
Joanne Jones University Neurology Unit, Box 165, Level 5 Block A, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK
&
Alastair Coles University Neurology Unit, Box 165, Level 5 Block A, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK
Pages 335-341 | Published online: 09 Jan 2014

Citations (79)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Francois Grand’Maison, Michael Yeung, Sarah A. Morrow, Liesly Lee, Francois Emond, Brian J. Ward, Pierre Laneuville & Robyn Schecter. (2018) Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion 34:8, pages 1419-1430.
Read now
Ghasem Ghalamfarsa, Mahmoud Mahmoudi, Mousa Mohammadnia-Afrouzi, Yaghoub Yazdani, Enayat Anvari, Abolghasem Hadinia, Amir Ghanbari, Maryam Setayesh, Mehdi Yousefi & Farhad Jadidi-Niaragh. (2016) IL-21 and IL-21 receptor in the immunopathogenesis of multiple sclerosis. Journal of Immunotoxicology 13:3, pages 274-285.
Read now
Barbara E. Ostrov. (2015) Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases. Immunological Investigations 44:8, pages 777-802.
Read now
Mark Willis & Neil P Robertson. (2014) Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety 13:8, pages 1115-1124.
Read now
Óscar Fernandez. (2014) Alemtuzumab in the treatment of multiple sclerosis. Journal of Inflammation Research 7, pages 19-27.
Read now
François Curtin & Hans-Peter Hartung. (2014) Novel therapeutic options for multiple sclerosis. Expert Review of Clinical Pharmacology 7:1, pages 91-104.
Read now
Patricia Katherine Coyle. (2014) Current evaluation of alemtuzumab in multiple sclerosis. Expert Opinion on Biological Therapy 14:1, pages 127-135.
Read now
JWL Brown & Alasdair J Coles. (2013) Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis. Drug Design, Development and Therapy 7, pages 131-138.
Read now
Luisa Klotz & Heinz Wiendl. (2013) Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy 13:6, pages 831-846.
Read now
Annika Deiß, Isabel Brecht, Axel Haarmann & Mathias Buttmann. (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Review of Neurotherapeutics 13:3, pages 313-335.
Read now
Daniel Ontaneda & Jeffrey A Cohen. (2013) The benefits and risks of alemtuzumab in multiple sclerosis. Expert Review of Clinical Immunology 9:3, pages 189-191.
Read now

Articles from other publishers (68)

Luka de Vos‐Hillebrand, Simon Fietz, Philip Hillebrand, Zsófi Kulcsár, Marie Yatou Diop, Sarah Hollick, Alexander Philippe Maas, Sebastian Strieth, Jennifer Landsberg & Dimo Dietrich. (2023) CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma . Pigment Cell & Melanoma Research.
Crossref
Lukas K. van Vugt, Marieke van der Zwan, Marian C. Clahsen-van Groningen, Madelon van Agteren, Daphne M. Hullegie-Peelen, Brenda C. M. De Winter, Marlies E. J. Reinders, Pedro Miranda Afonso & Dennis A. Hesselink. (2023) A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection. Transplant International 36.
Crossref
Mamatha Mandava, Jeffrey Lew, John F Tisdale, Emily Limerick, Courtney D Fitzhugh & Matthew M Hsieh. (2023) Thyroid and Adrenal Dysfunction in Hemoglobinopathies Before and After Allogeneic Hematopoietic Cell Transplant. Journal of the Endocrine Society 7:12.
Crossref
Grethe Åstrøm Ueland, Hans Olav Ueland, Ann-Elin Meling Stokland, Alok Bhan, Anne Schønberg, Stina T Sollid, Dina Edvarda Morgas, Trygve Holmøy, Kari Lima, Paal Methlie, Kristian Løvås, Øivind Torkildsen & Eystein S Husebye. (2023) Prevalence, Risk Factors, and Clinical and Biochemical Characteristics of Alemtuzumab-Induced Graves Disease. The Journal of Clinical Endocrinology & Metabolism.
Crossref
Parth Sharma, Annapurna Saksena, Adolfo Diaz, Yifan Pang & Parth Desai. (2023) Severe autoimmune intravascular hemolytic anemia in patients receiving alemtuzumab for multiple sclerosis. Blood Advances 7:11, pages 2534-2537.
Crossref
Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, Eleonora Cocco, Nicola De Stefano, Claudio Gasperini, Paolo Gallo, Carlo Pozzilli, Maria Trojano & Massimo Filippi. (2023) Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Therapeutic Advances in Neurological Disorders 16.
Crossref
Viviana Nociti & Marina Romozzi. (2022) Multiple Sclerosis and Autoimmune Comorbidities. Journal of Personalized Medicine 12:11, pages 1828.
Crossref
Merve Aktan Suzgun, Sami Omerhoca, Nilufer Kale & Ugur Uygunoglu. (2022) Prominent D‐dimer elevation and pretibial edema related to alemtuzumab treatment: A case report and literature review. Clinical and Experimental Neuroimmunology 13:4, pages 208-215.
Crossref
Richard Leckey, Liborio Borsellino, Andreea M Rawlings, John Ashkenas & Amit Suri. (2022) Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen. Multiple Sclerosis and Related Disorders 66, pages 104030.
Crossref
Nazanin Kiapour, Bing Wu, Yan Wang, Maryamsadat Seyedsadr, Sahil Kapoor, Xin Zhang, Manal Elzoheiry, Ezgi Kasimoglu, Yisong Wan & Silva Markovic-Plese. (2022) Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells. The Journal of Immunology 209:1, pages 49-56.
Crossref
P. Rodríguez de Vera Gómez, J. J. García-González, R. Ravé-García, R. López Ruiz, A. Torres-Cuadro, S. Eichau-Madueño, C. García-García & T. Martín-Hernández. (2022) Graves’ disease induced by Alemtuzumab in relapsing–remitting multiple sclerosis patients: an observational study in a reference center. Journal of Endocrinological Investigation 45:10, pages 1977-1990.
Crossref
Aigli G. Vakrakou, Dimitrios Tzanetakos, Maria-Eleptheria Evangelopoulos, George E. Fragoulis, Paraskevi Kazakou, Eleni Lekka, Nikolitsa Kafasi, John S. Tzartos, Elissavet Andreadou, Georgios Koutsis, Elias Gialafos, Antonios Dimitrakopoulos, Evanthia Zampeli, Dimitra Rontogianni, Stamatios Theocharis, Evangelia Zapanti, Panos-Alexis Stathopoulos, Maria Anagnostouli, Leonidas Stefanis & Constantinos Kilidireas. (2021) IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients. Journal of Neuroimmunology 361, pages 577759.
Crossref
Paulette Esperanza Walo-Delgado, Enric Monreal, Silvia Medina, Ester Quintana, Susana Sainz de la Maza, José Ignacio Fernández-Velasco, Paloma Lapuente, Manuel Comabella, Lluis Ramió-Torrentà, Xavier Montalban, Luciana Midaglia, Noelia Villarrubia, Angela Carrasco-Sayalero, Eulalia Rodríguez-Martín, Ernesto Roldán, José Meca-Lallana, Roberto Alvarez-Lafuente, Jaime Masjuan, Lucienne Costa-Frossard & Luisa Maria Villar. (2021) Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Frontiers in Immunology 12.
Crossref
Marco Biolato, Assunta Bianco, Matteo Lucchini, Antonio Gasbarrini, Massimiliano Mirabella & Antonio Grieco. (2021) The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs 35:8, pages 861-880.
Crossref
Gil‐Ran Kim, Won‐Ju Kim, Sangho Lim, Hong‐Gyun Lee, Ja‐Hyun Koo, Kyung‐Ho Nam, Sung‐Min Kim, Sung‐Dong Park & Je‐Min Choi. (2021) In Vivo Induction of Regulatory T Cells Via CTLA‐4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. Advanced Science 8:14, pages 2004973.
Crossref
Will Thomas, Theodora Foukaneli, Joyce Cosgrove, Dunecan Massey, Jeremy Woodward, Stephen Middleton, Martin Besser, Neil Russell, Irum Amin, Andrew Butler & Lisa Sharkey. (2021) Transplant‐associated thrombotic microangiopathy and immune haematological complications following intestine‐containing organ transplantation: experience from over 100 consecutive cases. British Journal of Haematology 193:5, pages 961-970.
Crossref
Sadia Nosher, Sehrish Fuad, Nupur Mishra, Zaid A Alrashid, Bindu Rathod, Devyani Mohan, Deepak M Basavanagowda, Arveen Kaur & Stacey E Heindl. (2021) Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis. Cureus.
Crossref
Fabian J. Bolte, Hartmut H.‐J. Schmidt & Bernhard Schlevogt. (2020) Immune‐Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis. Hepatology 73:1, pages 460-463.
Crossref
Ethan MeltzerSarah CampbellBenjamin EhrenfeldRoberto A. CruzLawrence SteinmanMatthew S. ParsonsScott S. ZamvilElliot M. FrohmanTeresa C. Frohman. (2020) Mitigating alemtuzumab-associated autoimmunity in MS. Neurology Neuroimmunology & Neuroinflammation 7:6.
Crossref
Clara Hilger, Christine Riedhammer, Evelyn Orsó & Robert Weissert. (2020) Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses. Frontiers in Immunology 11.
Crossref
Nataliya Prokopenko Buxbaum & Steven Z. Pavletic. (2020) Autoimmunity Following Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology 11.
Crossref
Simona Rolla, Alessandro Maglione, Stefania Federica De Mercanti & Marinella Clerico. (2020) The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. Cells 9:6, pages 1396.
Crossref
Mafalda Maria Laracho Seabra, Pedro Miguel Paredes Abreu, Maria Teresa Soares Mendonça, Joaquim Jorge Correia Silva Reis, Maria José Pontes Marques Sá & Joana Cruz Guimarães Ferreira Almeida. (2020) “Multiple sclerosis plus”: Does it influence the disease course?. Clinical and Experimental Neuroimmunology 11:2, pages 117-121.
Crossref
Paul D. E. Miller, John A. Snowden, Regis Peffault De Latour, Simona Iacobelli, Diderik-Jan Eikema, Cora Knol, Judith C. W. Marsh, Carmel Rice, Mickey Koh, Franca Fagioli, Sridhar Chaganti, Jürgen Finke, Rafael F. Duarte, Peter Bader, Dominique Farge, Jakob R. Passweg, J. Alejandro Madrigal & Carlo Dufour. (2019) Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation 55:2, pages 441-451.
Crossref
L. Scappaticcio, M. Castellana, C. Virili, G. Bellastella, M. Centanni, S. Cannavò, A. Campennì, R. M. Ruggeri, L. Giovanella & P. Trimboli. (2019) Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. Journal of Endocrinological Investigation 43:2, pages 219-229.
Crossref
Laura D Chin & Mohn’d AbuHilal. (2020) Ocrelizumab-induced alopecia areata—A series of five patients from Ontario, Canada: A case report. SAGE Open Medical Case Reports 8, pages 2050313X2091961.
Crossref
Azza Ismail, Basil Sharrack, Riccardo Saccardi, John J. Moore & John A. Snowden. (2019) Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. Current Opinion in Supportive & Palliative Care 13:4, pages 394-401.
Crossref
Tohid Gharibi, Arezoo Hosseini, Faroogh Marofi, Mona Oraei, Saeed Jahandideh, Meghdad Abdollahpour-Alitappeh, Vida Hashemi, Morteza Motallebnezhad, Zohreh Babaloo & Bezahd Baradaran. (2019) IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression. Immunology Letters 216, pages 12-20.
Crossref
Yvonne Benešová. (2019) Safety of multiple sclerosis treatment in the long term in relation to teriflunomide and alemtuzumab. Klinická farmakologie a farmacie 33:3, pages 29-36.
Crossref
Jonathan C. P. Roos, Carla Moran, V. Krishna Chatterjee, Joanne Jones, Alasdair Coles & Rachna Murthy. (2018) Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series. Eye 33:2, pages 223-229.
Crossref
Steffen Pfeuffer, Rene Schmidt, Frederike Anne Straeten, Refik Pul, Christoph Kleinschnitz, Marinus Wieshuber, De-Hyung Lee, Ralf A. Linker, Sebastian Doerck, Vera Straeten, Susanne Windhagen, Marc Pawlitzki, Christoph Aufenberg, Michael Lang, Christian Eienbroeker, Björn Tackenberg, Volker Limmroth, Brigitte Wildemann, Jürgen Haas, Luisa Klotz, Heinz Wiendl, Tobias Ruck & Sven G. Meuth. (2018) Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. Journal of Neurology 266:1, pages 165-173.
Crossref
N. V. Khachanova. (2019) Highly active multiple sclerosis: options for monoclonal antibody therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:10, pages 49.
Crossref
Luisa Klotz, Joachim Havla, Nicholas Schwab, Reinhard Hohlfeld, Michael Barnett, Stephen Reddel & Heinz Wiendl. (2019) Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Therapeutic Advances in Neurological Disorders 12, pages 175628641983657.
Crossref
Yara Dadalti Fragoso, Tarso Adoni, Joseph B. Bidin Brooks, Alessandro Finkelsztejn, Paulo Diniz da Gama, Anderson K. Grzesiuk, Vanessa Daccach Marques, Monica Fiuza K. Parolin, Henry K. Sato, Daniel Lima Varela & Claudia Cristina F. Vasconcelos. (2018) Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children. Neurology and Therapy 7:2, pages 207-232.
Crossref
Kavita Gulati & Stephen P. McAdoo. (2018) Anti–Glomerular Basement Membrane Disease. Rheumatic Disease Clinics of North America 44:4, pages 651-673.
Crossref
Patrick Aouad, Con Yiannikas, Suran L Fernando & John Parratt. (2018) A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881901.
Crossref
Serafeim Katsavos & Alasdair Coles. (2018) Alemtuzumab as Treatment for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine 8:10, pages a032029.
Crossref
Anna Randall, Saif Huda, Anu Jacob & Andrew J Larner. (2018) Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression. Practical Neurology 18:4, pages 320-322.
Crossref
David CroteauCharlene FlowersCorrinne G. KulickAllen BrinkerCindy M. Kortepeter. (2018) Acute acalculous cholecystitis. Neurology 90:18.
Crossref
Antònia Agustí Escasany. (2018) Reporting suspected adverse reactions to new commercialized medicines in real world. Multiple Sclerosis Journal 24:6, pages 816-817.
Crossref
Luminita Nicoleta Cima, Ioana Maria Lambrescu, Lavinia Stejereanu, Anca Colita, Reuven Or & Simona Fica. (2018) Graves’ orbitopathy after allogeneic bone marrow transplantation in a patient with Fanconi anemia – side effect of alemtuzumab therapy?. Clinical Case Reports 6:5, pages 867-870.
Crossref
Gregory M. T. Guilcher, Ravi Shah & Shalini Shenoy. (2018) Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non‐malignant diseases in children: A review. Pediatric Transplantation 22:2.
Crossref
Paolo Gallo, Diego Centonze & Maria Giovanna Marrosu. (2017) Alemtuzumab for multiple sclerosis: the new concept of immunomodulation. Multiple Sclerosis and Demyelinating Disorders 2:1.
Crossref
Keh Yann, Fran Jackson, Nazar Sharaf, Tatiana Mihalova, Paul Talbot, David Rog & Adrian Pace. (2017) Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 14, pages 1-3.
Crossref
Tanya Trinh, Anjana S. Haridas & Timothy J. Sullivan. (2016) Ocular Findings in Alemtuzumab (Campath-1H)-induced Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery 32:6, pages e128-e129.
Crossref
Daan JA Crommelin, Karl Broich, Chris Holloway, Bianca Meesen, Jana Lizrova Preiningerova, Jean-Louis Prugnaud & Beatriz Silva-Lima. (2016) The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?. Multiple Sclerosis Journal 22:2_suppl, pages 47-59.
Crossref
Teresa C. Frohman, Shin C. Beh, Eric J. Kildebeck, Ram Narayan, Katherine Treadaway & Elliot M. Frohman. (2016) Neurotherapeutic Strategies for Multiple Sclerosis. Neurologic Clinics 34:3, pages 483-523.
Crossref
Henrike J. Fischer, Ann‐Kathrin Witte, Lutz Walter, Hermann‐Josef Gröne, Jens Brandt & Holger M. Reichardt. (2016) Distinct roles of T‐cell lymphopenia and the microbial flora for gastrointestinal and CNS autoimmunity. The FASEB Journal 30:5, pages 1724-1732.
Crossref
Luca Prosperini, Fulvia Fanelli & Carlo Pozzilli. (2016) Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis. Journal of the Neurological Sciences 364, pages 145-147.
Crossref
Stefania De MercantiSimona RollaAngele CucciValentina BardinaEleonora CoccoAnton VladicSilva Soldo-ButkovicMario HabekIvan AdamecDana HorakovaPietro AnnovazziFrancesco NovelliLuca DurelliMarinella Clerico. (2016) Alemtuzumab long-term immunologic effect. Neurology Neuroimmunology & Neuroinflammation 3:1.
Crossref
Z. A. Goncharova, L. P. Sizyakina, R. A. Belovolova & V. A. Megeryan. (2016) Comorbid autoimmune pathology in patients treated with disease modifying drugs. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 116:10. Vyp. 2, pages 53.
Crossref
A. Coles, J. Jones & A. Compston. 2016. Translational Neuroimmunology in Multiple Sclerosis. Translational Neuroimmunology in Multiple Sclerosis 235 244 .
Kristen M. Williams, Danielle Dietzen, Abeer A. Hassoun, Ilene Fennoy & Monica Bhatia. (2014) Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease. Pediatric Blood & Cancer 61:12, pages 2307-2309.
Crossref
Oscar Fernandez. (2014) BG-12 (dimethyl fumarate) in the treatment of multiple sclerosis. Clinical Investigation 4:5, pages 441-451.
Crossref
A Salmen, R Gold & A Chan. (2014) Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. Clinical and Experimental Immunology 176:2, pages 135-148.
Crossref
Muna-Miriam Hoshi & Bernhard Hemmer. (2014) Therapie nach Einführung der neuen Immuntherapeutika. InFo Neurologie & Psychiatrie 16:4, pages 42-50.
Crossref
Claire M Rice. (2014) Disease modification in multiple sclerosis: an update. Practical Neurology 14:1, pages 6-13.
Crossref
Vibhav K. Bansal & Matthew N. Meriggioli. 2014. Neuromuscular Disorders in Clinical Practice. Neuromuscular Disorders in Clinical Practice 341 362 .
Algenes Alphius Aranha, Saima Amer, Elham Saleh Reda, Simon A. Broadley & Peter M. Davoren. (2013) Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review. Endocrine Practice 19:5, pages 821-828.
Crossref
Ban-Hock Toh, Tin Kyaw, Peter Tipping & Alex Bobik. (2013) Immune regulation by CD52-expressing CD4 T cells. Cellular & Molecular Immunology 10:5, pages 379-382.
Crossref
Michael J. Turner, Michael J. LaMorte, Nathalie Chretien, Evis Havari, Bruce L. Roberts, Johanne M. Kaplan & William M. Siders. (2013) Immune status following alemtuzumab treatment in human CD52 transgenic mice. Journal of Neuroimmunology 261:1-2, pages 29-36.
Crossref
L. Klotz, S.G. Meuth, B. Kieseier & H. Wiendl. (2013) Alemtuzumab bei schubförmig-remittierender multipler SkleroseAlemtuzumab for relapsing-remitting multiple sclerosis. Der Nervenarzt 84:8, pages 984-994.
Crossref
Grace K. Dy & Alex A. Adjei. (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA: A Cancer Journal for Clinicians 63:4, pages 249-279.
Crossref
Onajite Kousin-Ezewu & Alasdair Coles. (2013) Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects. Therapeutic Advances in Chronic Disease 4:3, pages 97-103.
Crossref
. (2013) Current World Literature. Current Opinion in Rheumatology 25:2, pages 275-283.
Crossref
Teya M. Tietje, Douglas R. Allington & Michael P. Rivey. (2013) Alemtuzumab: A Place in Therapy for Treatment of Multiple Sclerosis. International Journal of Clinical Medicine 04:10, pages 459-471.
Crossref
O H Kantarci, I Pirko & M Rodriguez. (2013) Novel Immunomodulatory Approaches for the Management of Multiple Sclerosis. Clinical Pharmacology & Therapeutics 95:1, pages 32-44.
Crossref
Daniel Ontaneda & Daniela Di Capua. (2012) Benefits versus risks of latest therapies in multiple sclerosis: a perspective review . Therapeutic Advances in Drug Safety 3:6, pages 291-303.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.